For patients with metachronous low burden mCSPC on conventional imaging being recommended for systemic therapy, 51% responded ...

APCCC Diagnostics annual meeting featured a session on what we should know for PSMA radioligand therapy and a presentation by ...

APCCC Diagnostics annual meeting featured a session on how to monitor metastatic prostate cancer and a presentation by Dr.

(UroToday.com) The 2025 APCCC Diagnostics annual meeting featured a session on how to monitor metastatic prostate cancer and ...

Dr. Tombal notes that from the ENZAMET trial, 1 we have made significant progress in survival among men with newly diagnosed mHSPC, but there are still 30-40% of men that die at 5 years, and many will ...

(UroToday.com) Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics 2025 held in Lugano, Switzerland was host to a session addressing the contemporary management of metastatic prostate ...

Based on work Dr. Petrylak presented at ASCO 2024 looking at dose adjustment and efficacy of enfortumab vedotin, most ...

GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Glenn Bauman discussing a prospective ...

APCCC Diagnostics annual meeting featured a session on how to monitor metastatic prostate cancer and a presentation by Dr. Alexander Wyatt discussing when we should assess biology with ctDNA. Cell ...

(UroToday.com) The Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics 2025, held in Lugano, Switzerland, on February 27 th and 28 th, was host to a session addressing the contemporary ...

(UroToday.com) The Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics 2025 held in Lugano, Switzerland was host to a session addressing the contemporary management of biochemically ...

In the initial publication in 2021, the KETYNOTE-564 trial demonstrated that adjuvant pembrolizumab was associated with ...